This technology involves pharmaceutical compositions for the treatment and prevention of hypertension, as well as food compositions for the improvement and prevention of hypertension, containing as an active ingredient a compound with a specific structure isolated from the extract of the medicinal plant Nardostachys jatamansi, or its pharmaceutically acceptable salts. This compound inhibits soluble epoxide hydrolase, which is involved in blood pressure regulation, and also reduces NO production.
Soluble epoxide hydrolase breaks down epoxy fatty acids that relax blood vessels and suppress inflammation, leading to increased blood pressure and reduced vascular function. Consequently, inhibitors that block this enzyme have gained attention as therapeutic targets for hypertension, heart disease, and atherosclerosis. However, there has been a lack of inhibitors with proven safety, making the development of substances derived from edible natural products with fewer concerns regarding side effects an urgent task.
This technology is configured to utilize the vascular-protective effects of compounds obtained from Nardostachys jatamansi, which prevent the hydrolysis of epoxy fatty acid intermediates, for hypertension management. The food composition can also be formulated as a health functional food. As a natural plant-derived ingredient, it offers expanded development pathways for both pharmaceuticals and food products. It can be applied to new hypertension drug candidates, health functional foods for blood pressure management, and supplements for preventing hypertensive heart disease, enabling the creation of a new line of natural product-based blood pressure management products that target different enzymes than existing blood pressure medications.
WO2013-129769A1
